Table 1 Results in the MITT populations of pivotal trials of echinocandins for therapy of invasive fungal infections [45, 55–57]
| Â | Anidulafungin | Caspofungin | Micafungin | |
|---|---|---|---|---|
Comparator | Fluconazole | Amphotericin B deoxycholate | Liposomal amphotericin B | Caspofungin **** |
Patient number (MITT), n | 127 / 118 | 109 / 115 | 247 / 247 | 191 / 188 |
Candidemia, % | 91 / 87 | 82.6 / 79.1 | 84.2 / 85.8 *** | 85.3 / 85.6 |
Infection with C. non -albicans, % | 36 / 41 * | 64.4 / 45.9 [p = 0.0009] | 62.4 / 58.9 *** | 54.5 / 60.6 |
Neutropenia, % | 2.4 / 3.4 | 12.8 / 8.7 | 11.9 / 7.9 *** | 11.5 / 5.9 |
Switched to oral fluconazole, % | 26.0 / 28.0 | 24.8 / 34.8 | Not allowed | 20.9 / 21.2 |
Global success at end of IV therapy, % | 75.6 / 60.2 [p = 0.01] | 73.4 / 61.7 [p = n.s.] | 74.1 / 69.6 p = n.s.] | 76.4 / 72.3 p = n.s.] |
Global success at end of all therapy, % | 74.0 / 56.8 [p < 0.02] | 72.5 / 61.7 [p = n.s.] | 74.1 / 69.6 [p = n.s.] | 74.9 / 70.2 [p = n.s.] |
Global success at 2 weeks follow up, % | 64.6 / 49.2 [p < 0.02] | 63.6 / 53.8 [p = n.s.] | Not reported | 54.5/ 50.5 [p = n.s.] |
Global success at 6 weeks follow up, % | 55.9 / 44.1 [p = n.s.] | 56.6 /47.5 ** [p = n.s.] | Not reported | 46.6 / 42.6 [p = n.s.] |
Microbiological success at end of IV therapy, % | 88.1 / 76.2 | Not reported | Not reported | 88.5 / 84.0 |
Time to negative blood cultures, days | 2 / 5 (C. albicans)[59] | Not reported | 3 / 4 *** | 2 / 2 |
Persistent infection, % | 6.3 / 14.4 [p = n.s.] | 8.3 / 8.7 [p = n.s.] | 8.9 / 8.4 *** [p = n.s.] | 5.8 / 9.6 [p = n.s.] |
Mortality rate (ITT), % | 22.8 / 31.4 [p = n.s.] | 34.2 / 30.4 [p = n.s.] | 40 / 40 [p = n.s.] | 29.0 / 26.4 |